Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study

By P. Gurbel, K. Bliden, K. Butler, U. Tantry, T. Gesheff, Cheryl Wei, R. Teng, Mark J. Antonino, Shankar B. Patil, Arun Karunakaran and 6 more. Circulation, 2009

877 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/29fa3c65f01c30dca2c34f78c8adb0e2db4fd2e7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. V. Chandrasekhara
2. M. Khashab
3. V. Muthusamy
4. A. Shaukat
5. S. Pasha
6. D. Early
7. Ruben Acosta
8. B. Cash

Citations in the corpus

• The management of antithrombotic agents for patients undergoing GI endoscopy. (2016, background): “Unlike clopidogrel (Plavix) and prasugrel (Effient), the reversible inhibition of the P2Y12 receptor permits a shorter interval of discontinuation, 3 to 5 days, to recover adequate platelet function.(49) In January 2014 the FDA approved a first-in-class antiplatelet medication, vorapaxar (Zontivity)”